For research use only. Not for therapeutic Use.
Vupanorsen（Cat No.:I038221）is an investigational antisense oligonucleotide drug being developed for the treatment of dyslipidemia, particularly high levels of triglycerides and other lipid-related conditions. It works by targeting and inhibiting the production of apolipoprotein C-III (ApoC-III), a protein that regulates triglyceride metabolism. By reducing ApoC-III levels, Vupanorsen aims to lower triglyceride levels and improve lipid profiles, potentially reducing the risk of cardiovascular diseases. Currently in clinical trials, the drug’s safety, efficacy, and long-term effects are being evaluated, with promising results for managing lipid abnormalities in patients with cardiovascular risk.
| Catalog Number | I038221 |
| CAS Number | 2097587-62-5 |
| Synonyms | Vupanorsen; vupanorsenum; vupanorsen; AKCEA-ANGPTL3-LRx; ISIS 703802; UNII-A7YG; WHO 11175. 62NHZ6; |
| Molecular Formula | C296H434N86O152P20S13 |
| Purity | 98% |
| Target | Antisense Oligonucleotides |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
